DI 23022.836: Neurodegeneration with Brain Iron Accumulation- Type 1 and 2
Effective Dates: 11/18/2016 - Present TN 7 (08-12)
- DI 23022.836 Neurodegeneration with Brain Iron Accumulation- Type 1 and 2
- COMPASSIONATE ALLOWANCE INFORMATION
- NEURODEGENERATION with BRAIN IRON ACCUMULATION - TYPE 1 and 2
- NBIA-1; NBIA-2; Hallervorden-Spatz Syndrome; (HSS); Pantothenate Kinase Associated Neurodegeneration; PKAN; Pigmentary Degeneration of Globus Pallidus and Substantia Nigra Red Nucleus, Neuroferritinopathy, Infantile; Neuroaxonal Dystrophy; INAD
- Neurodegeneration with Brain Iron Accumulation (NBIA) is a rare inherited neurological movement disorder that is characterized by progressive degeneration of the nervous system. NBIA Type 1 (NBIA-1) and Type 2 (NBIA-2) are caused by one or more genetic mutations that result in iron being deposited in regions of the brain that control movement and balance; the most common mutation involves the PANK2 gene. Symptoms of this disease usually develop during childhood, and may include distorting muscle contractions of the limbs, face or trunk; involuntary writhing muscle movements, coordination difficulties, difficulty swallowing or speaking, confusion, disorientation, seizures, visual impairment, and dementia.
DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM CODING
- Diagnostic testing: The diagnosis of NBIA is based on medical and family history, and neurologic exam. Neurologic signs include parkinsonism, abnormal postures and movements (dystonia), ataxia, muscle rigidity, spasticity, and cognitive impairment. MRI of the brain can be helpful to demonstrate the accumulation of iron in the basal ganglia. Although there are laboratory tests for the genetic mutations of NBIA-1 and NBIA-2, they are expensive and not widely available.
- ICD-9: 333.0
ONSET AND PROGRESSION
- NBIA usually begins between 7 and 15 years of age, although it may also present earlier (infantile onset) or later (adult onset). The severity and rate of progression correlates with the age at onset, especially in infants and young children. Symptoms and signs such as dystonia and spasticity eventually limit the ability to walk, and usually progress to the use of a wheel chair by mid-teens. Life expectancy is variable, but the average survival after diagnosis is 10-12 years. Death can occur secondary to dystonia, impaired swallowing, and aspiration pneumonia.
- There is currently no cure for NBIA. Treatment is symptomatic and supportive. Iron chelating medications have been attempted without significant effect. Individuals may benefit somewhat from pharmacological therapy for specific symptoms, such as rigidity. Physical, speech, and occupational therapies can also help with activities of daily living.
SUGGESTED PROGRAMMATIC ASSESSMENT* Suggested MER for evaluation:
- * Longitudinal clinical history and examination that describe diagnostic features, family history, and neurologic exam.
- * Imaging studies such as an MRI.
Suggested Listings for Evaluation: DETERMINATION
REMARKS Meets Listing 11.17 12.02 111.17
* Adjudicators may, at their discretion, use the Medical Evidence of Record or Listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.
x← This means that the line was removed and was added – in other words, the "Effective Dates" line at the top of the document has been updated to reflect that the new version is effective as of the date the change was made.